Oncologists, aware that patients are paying the costs of expensive cancer drugs, are declining to prescribe medicines that have scant or no effect.» Read More
Marijn Dekkers, CEO of drug and chemicals company Bayer, tells CNBC that falling earnings in the material sciences division may make it harder to achieve its earnings goals for the year.
China is preventing a GlaxoSmithKline executive from leaving the country as police accuse the British drugmaker of bribing officials and doctors, the drugmaker says.
A federal judge in Kansas City, Kansas, ordered Dow Chemical Co on Wednesday to pay $1.2 billion in a price-fixing case involving chemicals used to make foam products in cars.
European shares closed higher on Monday after Italy's new Prime Minister announced his reform plans in his maiden speech to parliament.
Germany's Bayer has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider.
Marijn Dekkers, CEO of Bayer, says the positive outlook for 2013 is driven by strong projected strong growth in Healthcare and Crop Sciences and explains how the company is heavily investing in its growth.
Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.
Marijn Dekkers, CEO of Bayer, tells CNBC why the company's development of new drugs make him confident of reaching targets set of 2.5 billion euros in drug sales.
Syngenta, the world's largest agrochemicals company, said it was confident ahead of the upcoming planting season and will hike its dividend 19 percent after it posted a full-year net profit that beat expectations.
Weak GDP data for the U.K. wasn't enough to stop European shares rising on Friday as Germany's DAX Index reached a level not seen since January 2008 after business climate data was released.
Marijn Dekkers, CEO of Bayer, talks to CNBC about the outlook for the pharmaceutical industry
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
Marijn Dekkers, CEO of Bayer, explains to CNBC that while Bayer has felt increased pressure on drug pricing from governments, its success in research and development has the company positioned for success.
Bayer CEO Marijn Dekkers says the firm's $1.2 billion purchase of Schiff Nutrition will help Bayer build its position in consumer healthcare.
*Cheuvreux cuts Bayer to outperform from selected list. Reuters Station users, click. 1568. Reuters Station users, click. 4899.
*Jefferies cuts AstraZeneca PLC price target to 3,000 p from 3,100 p;. *Jefferies raises Bayer AG price target to 71 euros from 65 euros;. *Jefferies raises Eli Lilly price target to $36 from $35; rating.
FRANKFURT, Oct 9- Bayer AG:. *Says European commission gives green light for flexyess. *Says health authorities of the EU member states will grant national approvals.
Shares in CIMB Thai Bank Pcl jumped as much as 23 percent to 2.96 baht, the highest since Nov. 5, 2010, after a newspaper reported that its parent, CIMB Group Holdings Bhd, planned to buy a stake in Bank of Ayudhya.
DEUTSCHE TELEKOM Indicated 0.1 percent lower. Deutsche Telekom is in talks to merge its T-Mobile USA unit with smaller rival MetroPCS, in a move that could pave the way for the German company to eventually exit the U.S. wireless market.
WASHINGTON, Oct 2- U.S. antitrust regulators found no wrongdoing in a deal made four years ago between German drugmaker Bayer AG and a division of Teva Pharmaceuticals to end patent litigation over the popular Yasmin birth control pill.